Market Overview

Chardan Capital Downgrades Amicus Therapeutics to Neutral, Lowers Price Target to $15

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for FOLD

DateFirmActionFromTo
Aug 2018Chardan CapitalDowngradesBuyNeutral
Feb 2018Leerink SwannMaintainsOutperformOutperform
Jul 2017BairdMaintainsOutperform

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (FOLD)

The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

23 Stocks Moving In Friday's Pre-Market Session